期刊
JOURNAL OF HEMATOLOGY & ONCOLOGY
卷 13, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s13045-020-00910-5
关键词
CAR-T cell therapy; Hematological malignancies; Immune therapy
资金
- Science and Technology Innovation Special Project of Social Undertakings and People's Livelihood Security of Chongqing [CSTC2016shms-ztzx10003]
- Clinical Project of Major Technology Innovation of Army Medical University [CX2019LC111]
- Hospital-level Clinical Innovation Military-Civilian Special Project of Army Medical University [2018JSLC0020]
- Special Funding for the Frontiers of Military Medical Basics [2018YQYLY002]
Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for relapsed or refractory tumors, particularly for hematological malignancies. Although the initially approved anti-CD19 CAR-T therapy has produced impressive outcomes, setbacks such as high relapse rates and resistance were experienced, driving the need to discover engineered CAR-T cells that are more effective for therapeutic use. Innovations in the structure and manufacturing of CAR-T cells have resulted in significant improvements in efficacy and persistence, particularly with the development of fourth-generation CAR-T cells. Paired with an immune modifier, the use of fourth-generation and next-generation CAR-T cells will not be limited because of cytotoxic effects and will be an efficient tool for overcoming the tumor microenvironment. In this review, we summarize the recent transformations in the ectodomain, transmembrane domain, and endodomain of the CAR structure, which, together with innovative manufacturing technology and improved cell sources, improve the prospects for the future development of CAR-T cell therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据